About the Company
Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MNTA News
Global Cerebral Vein Thrombosis Treatment Market to Reach US$ 611 Million by 2033
Cerebral Vein Thrombosis Treatment Market is projected to 12.3% CAGR, is expected to reach an estimated value of US$ 611 ...
Arthritis Patients - Cigna's Evernorth To Offer Humira Biosimilar At No Out-of-Pocket Cost
Evernorth Health Services said its Accredo arm will make a Humira biosimilar available to patients with no out-of-pocket ...
FcRn Inhibitor Market is Predicted to Grow Rapidly During the Study Period (2020–2034) | DelveInsight
As per DelveInsight’s analysis, the FcRn inhibitor market is anticipated to grow at a significant CAGR by 2034. Leading FcRn inhibitor companies such as Johnson & Johnson, Immunovant, and others are ...
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
Goldman Sachs and Leerink Partners are acting as lead joint book-running managers for the proposed offering. Evercore ISI, Guggenheim Securities and BMO Capital Markets are also acting as joint ...
Loading the latest forecasts...